EUCTR2006-000720-13-AT进行中（未招募）不适用
Double-blind, randomised, placebo-controlled, multi-centre phase II study to evaluate the efficacy and safety of three different dosages of oral Trichuris suis ova (TSO) suspension in active Crohn’s disease - TSO vs. placebo in active Crohn’s disease
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Signed informed consent,
- •2. Man or woman between 18 and 75 years of age,
- •3. Established diagnosis of Crohn's disease (CD) confirmed by endoscopic and histological, or endoscopic and radiological criteria, all of which since at least 3 months prior to screening,
- •4. Localisation of CD either in terminal ileum (L1), in colon (L2) or ileocolitis (L3), all without upper gastrointestinal involvement (- L4) according to the Montreal classification (2005),
- •5. CDAI =220 and = 350 at baseline,
- •6. Serum CRP level = 2 x upper limit of normal (ULN) or stool Calprotectin > ULN at screening,
- •7. Haemoglobin = 10 g/dl at screening,
- •8. White blood cell count = 13.0 Gpt/L at screening,
- •9. Platelet count = lower limit of normal at screening,
- •10. Negative pregnancy test in females of childbearing potential,
- •11. Women of child-bearing potential have to apply during the entire duration of the study a highly effective method of birth control, which is defined as those which result in a low failure rate (i.e., less than 1% per year) when used constantly and correctly such as implants, injectables, combined oral contraceptive method, or some IUDs. The investigator is responsible for determining whether the subject has this adequate birth control for study participation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 376
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 24
排除标准
- •1. Known Crohn's lesions in the upper GI-tract (up to and including the jejunum) with present symptoms,
- •2. Bowel surgery within the last 3 months prior to baseline,
- •3. Resection of more than 50 cm of the ileum,
- •4. Ileostomy or colostomy,
- •5. Septic complications,
- •6. Evidence of infectious diarrhoea (i.e., pathogenic bacteria or Clostridium difficile toxin in stool culture),
- •7. Abscess, perforation, active fistulas, or active perianal lesions,
- •8. Immediate surgery required (e.g., major stenosis, serious bleeding, peritonitis, ileus),
- •9. Clinical signs of stricturing disease,
- •10. Parenteral or tube feeding,
- •11. Abnormal hepatic function (ALT or ALP > 2.5 x ULN at screening), liver cirrhosis, or portal hypertension,
- •12. Abnormal renal function (Cystatin C > ULN) at screening,
- •13. Acute EBV infection at screening,
- •14. Any severe concomitant cardiovascular, renal, endocrine, or psychiatric disorder, which in the opinion of the investigator might have an influence on the patient's compliance or the interpretation of the results,
- •15. Any condition associated with significant immunosuppression,
- •16. Active malignancy or treatment with anticancer drugs during the last 5 years. Patients with a history of cancer and at least five years of uneventful follow up and no signs of recurrence may be eligible as well as patients with treated, non-metastatic cancers (e.g., basalioma),
- •17. Treatment with immunosuppressants or anti-cancer drugs, e.g., anti-TNF- a agents, anti-integrin agents, azathioprine or 6-MP, 6-thioguanine, methotrexate, tacrolimus, cyclophosphamide, or cyclosporine within the last 3 months prior to baseline,
- •18. Treatment with antibiotics (e.g., metronidazole or ciprofloxacin), antiparasitic medications within the last 2 weeks prior to baseline,
- •19. Treatment with topical or systemic glucocorticosteroid within the last 4 weeks prior to baseline, or within the last 8 weeks, if patients have been treated for longer than 3 months,
- •20. Patients known to be steroid-dependent or refractory, as defined in ECCO consensus guideline 2010,
- •21. Patients being unresponsive to both treatment with a biologic (e.g., anti-TNF-a agents or anti-integrin agents) AND treatment with a thiopurine (i.e., azathioprine, 6-MP, or 6-thioguanine),
- •22. Application of non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks before baseline visit for more than 3 consecutive days, except acetylsalicylic acid = 350 mg/d which is allowed,
- •23. Immunisation with live vaccines within 12 weeks prior to baseline or during the study,
- •24. Travelling within the last 12 weeks prior to baseline or during study participation to countries outside of Europe, U.S.A., or Canada,
- •25. Well-founded doubt about the patient's cooperation, e.g., because of addiction to alcohol or drugs,
- •26. Existing or intended pregnancy or breast-feeding,
- •27. Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in the TSU-2/CDA trial and having received study drug.
研究者
相似试验
进行中（未招募）
1 期
Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study on the efficacy and tolerability of budesonide capsules versus placebo for maintenance of remission in patients with collagenous colitis - SOIBD Collagenous Colitis Maintenance Study (SCCMS)Collagenous colitisMedDRA version: 8.1 Level: LLT Classification code 10048928 Term: Colitis collagenousEUCTR2007-001315-31-BEDr. Falk Pharma GmbH92
进行中（未招募）
不适用
Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study on the efficacy and tolerability of budesonide capsules versus placebo for maintenance of remission in patients with collagenous colitis - SOIBD Collagenous Colitis Maintenance Study (SCCMS)Collagenous colitisMedDRA version: 13.1Level: PTClassification code 10048928Term: Colitis collagenousSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2007-001315-31-DKDr. Falk Pharma GmbH110
进行中（未招募）
不适用
Study to compare the combination of ursodeoxycholic acid andbudesonide with the combination of ursodeoxycholic acid and placebo inthe treatment of primary biliary cirrhosisPBC patients with an incomplete response to UDCA treatment defined by the failure to achieve s-AP levels < 1.5x upper limit of normal after at least 6 months of treatment with UDCA and with inflammatory activity in the histological assessment of the liverMedDRA version: 18.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871EUCTR2007-004040-70-LTDr. Falk Pharma GmbH144
进行中（未招募）
不适用
Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study on the efficacy and tolerability of budesonide capsules versus placebo for maintenance of remission in patients with collagenous colitis - SOIBD Collagenous Colitis Maintenance Study (SCCMS)Collagenous colitisMedDRA version: 14.1Level: LLTClassification code 10048928Term: Colitis collagenousSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2007-001315-31-DEDr. Falk Pharma GmbH110
进行中（未招募）
不适用
Study to evaluate the effectiveness and safety of 3 doses ofembryonated eggs of the porcine whipworm compared to placebo(dummy drug) in the treatment of active Crohn's disease.Induction of remission in active Crohn´s diseaseMedDRA version: 14.1Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2006-000720-13-DKDr. Falk Pharma GmbH400